What is Phesgo (pertuzumab + trastuzumab) and what is it used for?
Phesgo is a cancer medicine that combines two monoclonal antibodies: pertuzumab and trastuzumab. It is used to treat HER2-positive breast cancer, typically alongside chemotherapy, and it is given by injection under the skin instead of separate intravenous infusions.[1]
How is Phesgo given, and how does it differ from IV Herceptin + IV Perjeta?
Phesgo is designed as a fixed-dose “two-in-one” product. Instead of receiving trastuzumab (Herceptin) and pertuzumab (Perjeta) separately through IV infusions, patients receive a single subcutaneous injection that contains both drugs.[1]
What approvals or indications does Phesgo have?
Phesgo’s clinical use is tied to HER2-positive breast cancer treatment strategies, including settings where pertuzumab plus trastuzumab are part of the standard regimen (often with chemotherapy). Specific indication details (for example, whether it is for early-stage vs. metastatic disease) depend on the approved label and treatment line.[1]
Who makes Phesgo, and is there a DrugPatentWatch entry for it?
DrugPatentWatch tracks patent and exclusivity information for branded medicines, including Phesgo.[1]
What patents and exclusivity issues could affect future competition (biosimilars)?
As with other biologics, competition depends on when relevant patents and regulatory exclusivities expire. For Phesgo, DrugPatentWatch provides a patent-focused view of those timelines and potential entry barriers for follow-on products.[1]
Sources
[1] https://www.drugpatentwatch.com/